Biotron Limited (ASX:BIT) has announced that Glenn Gilbert has commenced as Chief Executive Officer and Executive Director effective 9 November 2026, bringing forward his previously announced start date of 18 January 2027.

Key Points

  • Glenn Gilbert commenced as CEO and Executive Director on 9 November 2026, ahead of his previously announced start date of 18 January 2027.
  • Immediate priorities include reviewing Biotron's development portfolio, defining the next-stage strategy for SedRx, and evaluating development and partnering pathways for the company's assets.
  • The review will also consider development and commercialisation strategy for BIT-HBV001 and additional potential neurology opportunities.
  • Mr Gilbert's initial director's interest notice discloses nil securities held, either as registered holder or otherwise.

Early Commencement of Glenn Gilbert as CEO and Executive Director

Biotron Limited disclosed on 9 November 2026 that Glenn Gilbert has commenced as Chief Executive Officer and Executive Director, effective immediately. His original commencement date had been announced as 18 January 2027. According to the filing, Mr Gilbert's experience spans quality, regulatory and clinical development, commercialisation, manufacturing, international business development and capital raising. The company stated that his earlier commencement enables it to immediately progress a strategic and operational review of its development portfolio and establish clear priorities for the next phase of the company's development.

SedRx and Broader Portfolio Under Strategic Review

The filing states that a key focus for Mr Gilbert will be SedRx, Biotron's next-generation alfaxalone-based general anaesthetic, including its regulatory, clinical, manufacturing and partnering pathway. The review will also consider the development and commercialisation strategy for the company's broader portfolio, including BIT-HBV001, described as a novel antiviral candidate, and additional potential neurology opportunities. The filing notes that the earlier commencement will also facilitate engagement with Biotron's key stakeholders, development partners and the broader investment community.

Board and CEO Statements on Strategic Direction

Chairman Paul Kasian stated in the filing that Mr Gilbert's earlier commencement allows the company to accelerate an important strategic review of Biotron's portfolio and establish clear priorities for the next stage of the company's development. CEO and Executive Director Glenn Gilbert said his immediate focus will be to work with the board and advisers to establish clear development priorities, define the regulatory and commercial pathways for key programs, and ensure capital is directed toward activities capable of delivering meaningful shareholder value. The board of directors approved the filing.